• Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma click here

Kazia is a Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.